New Hope for Parkinson's Patients: Immunis Licenses Dyskinesia Drug KORA

IRVINE, CA – March 05, 2026 – In a significant move that could bring relief to millions, clinical-stage biotech company Immunis, Inc. has announced an exclusive licensing agreement with global innovation leader Toray Industries for a new drug candidate aimed at a debilitating side effect of Parkinson's disease treatment. The drug, which Immunis will develop under the name KORA, targets the uncontrollable, involuntary movements known as dyskinesia, a condition that profoundly impacts patients' quality of life.

Immunis has already submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA), signaling its intent to fast-track KORA into a Phase I clinical trial. The agreement grants the Irvine-based company exclusive rights to develop and commercialize the treatment in major global markets, including the United States, Canada, and the European Union.

Addressing a Debilitating Complication of Parkinson's

Parkinson's disease, a neurodegenerative disorder with a global prevalence that has doubled in the last 25 years, affects more than 8.5 million people worldwide. The standard and most effective treatment for its primary motor symptoms—such as tremors, stiffness, and slowness of movement—remains Levodopa (L-DOPA). However, this therapeutic cornerstone comes with a severe long-term complication.

An estimated 80% of individuals with Parkinson's who receive L-DOPA therapy for a decade will develop L-DOPA-induced dyskinesia (LID). This condition is characterized by erratic, involuntary, and often dance-like movements that can affect the limbs, torso, and face. For patients, the impact is devastating. Simple daily activities like eating, writing, or dressing become monumental challenges, leading to an increased risk of falls, significant emotional distress, and social isolation. Managing LID is one of the most significant unmet needs in modern Parkinson's care.

The Science of KORA: A New Approach to an Old Problem

The scientific promise of KORA lies in its novel mechanism of action. Known generically as Nalfurafine Hydrochloride, KORA is the world's first selective kappa-opioid receptor (KOR) agonist. These receptors are widely distributed in the central nervous system and are involved in modulating dopamine pathways, which are central to the development of dyskinesia.

By targeting a non-dopaminergic pathway, KORA offers a potential alternative to simply adjusting L-DOPA dosages, a delicate balancing act that often forces clinicians and patients to choose between controlling Parkinson's symptoms and managing dyskinesia. The current primary treatment for LID, amantadine, works on a different neurotransmitter system, but not all patients respond, and it can have its own side effects. The development of new compounds with different mechanisms is therefore a critical area of research.

Preclinical data published in a rat model of Parkinson's disease showed that KORA effectively reduced L-DOPA-induced dyskinesia symptoms, providing the scientific foundation for Immunis's clinical development plan. While KOR agonists have historically presented challenges due to potential side effects like sedation or mood changes, KORA's selectivity may offer a more favorable profile, a key factor the upcoming Phase I trial will begin to evaluate.

A Strategic Expansion for Immunis

For Immunis, a company primarily focused on developing stem cell-derived therapies for age-related muscle and metabolic diseases, the KORA licensing deal represents a bold and strategic expansion into the highly competitive neurodegenerative market. It diversifies the company's research pipeline and positions it as a player in the search for solutions to one of neurology's most pressing problems.

“Immunis is thrilled to expand our research pipeline to include a common and serious complication affecting Parkinson's disease patients,” said Mark Cabato, Chief Business Officer at Immunis, in the company's press release. “Our collaboration with Toray reflects our continued commitment to maximizing healthspan and minimizing disease through the advancement of transformative medicine.”

The partnership also highlights the business strategy of Toray, a Japanese multinational giant known for its advanced materials and a robust “open-innovation” approach in its pharmaceutical division. By licensing KORA to a specialized biotech like Immunis, Toray leverages its discovery engine while partnering with a focused team to navigate the complex and costly path of clinical development and commercialization.

The Long Road Ahead: Navigating Clinical Trials and Regulatory Hurdles

The IND submission to the FDA is a critical milestone, but it marks the beginning, not the end, of a long and arduous journey. The path to bringing a new neurological drug to market is notoriously challenging, with high costs and a low probability of success. Drug development in neurology can take over a decade and cost hundreds of millions, if not billions, of dollars.

The initial Phase I trial will focus on assessing KORA's safety, tolerability, and pharmacokinetic profile in a small group of participants. If successful, Immunis will need to conduct larger, more complex Phase II and Phase III trials to prove the drug's efficacy in reducing dyskinesia without compromising the benefits of L-DOPA or causing unacceptable side effects. Each stage presents significant scientific and financial hurdles.

Despite the challenges, the initiation of this clinical program represents a tangible step forward. For the millions of Parkinson's patients and their families who live with the daily reality of dyskinesia, the development of a novel treatment like KORA provides a crucial glimmer of hope on the horizon.